Brincidofovir is a lipid-conjugated prodrug and antiviral agent indicated for the treatment of human smallpox disease caused by the variola virus. By utilizing a lipid-conjugated design, this medication… Read more
Brincidofovir is a lipid-conjugated prodrug and antiviral agent indicated for the treatment of human smallpox disease caused by the variola virus. By utilizing a lipid-conjugated design, this medication enhances the intracellular delivery of its active metabolite, cidofovir, while aiming to reduce systemic toxicity compared to the parent drug. In pharmaceutical development and manufacturing, maintaining rigorous quality standards is critical. This category provides essential reference standards, related impurities, metabolites, and stable isotope labelled compounds required for comprehensive impurity profiling and method validation. Laboratories rely on these high-quality materials to ensure accurate quantification and structural verification during analytical testing and quality control processes, supporting compliance with regulatory requirements throughout the drug development lifecycle.